May 29, 2020
FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women
Apr 13, 2020
USA Fibroid Centers Now Offer the Safety and Convenience of Telemedicine Consultations During the COVID-19 Pandemic
Aug 05, 2019
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
Jan 08, 2019
Dr. Teresa O Of The Vascular Birthmark Institute Of New York Named 2018 Physician Of The Year By The Vascular Birthmark Foundation
Sep 13, 2018
Dr. James St. George, M.D. Launches Innovative New Fibroid Center in Jacksonville
Aug 22, 2018
AbbVie Announces Positive Topline Results from Phase 3 Extension Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Jul 10, 2018
Recursion Receives FDA Clearance of Investigational New Drug Application to Initiate First Clinical Trial of REC-994 in Cerebral Cavernous Malformation
Mar 13, 2018
AbbVie Announces Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Feb 21, 2018
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
Sep 15, 2017
First-ever Uterine Fibroid Patient Registry Aims to Shed Light on Burden for Thousands of Canadian Women
Aug 29, 2017
Bayer announces enrollment of first U.S. patient in Phase III trials of vilaprisan in uterine fibroids
Aug 14, 2017
Familial Adenomatous Polyposis - Pipeline Review, H2 2017